DHRS3 inhibitors encompass a spectrum of chemical compounds that exert their inhibitory effect through modulation of retinoid metabolism and signaling pathways. Retinal and 13-cis-Retinoic acid are two such compounds; the former competes with DHRS3's natural substrate, reducing its enzymatic activity, while the latter serves as a negative regulator of the retinoid signaling pathway, which is intricately connected with DHRS3 function. Similarly, Citral and Disulfiram act upon related metabolic pathways to indirectly suppress DHRS3 activity; Citral prevents the conversion of retinoids, thus affecting substrate availability for DHRS3, and Disulfiram, by inhibiting aldehyde dehydrogenase, leads to increased levels of retinal, which competes with DHRS3's action. Retinoic Acid and 4-Hydroxyphenylretinamide also diminish DHRS3 activity through their influence on retinoic acid levels and retinoid metabolism, pathways essential for DHRS3 functionality, by modulating the availability of DHRS3 substrates.
Additional compounds such as Acitretin, Bexarotene, and Adapalene indirectly inhibit DHRS3 by altering the complex retinoid metabolic processes, leading to downregulation of the enzyme's activity. Moreover, Aminobenzaldehyde, while acting as a general dehydrogenase inhibitor, potentially decreases DHRS3 activity through substrate competition. The non-specific dehydrogenase inhibitor Gossypol could extend its inhibitory effects to DHRS3, further diminishing the enzyme's role in retinoid metabolism. Lastly, Methotrexate, although primarily targeting dihydrofolate reductase, might exert an indirect inhibitory effect on DHRS3 by disrupting folate metabolism, which can indirectly influence retinoid pathways and DHRS3's activity. Collectively, these DHRS3 inhibitors, each with a distinct biochemical mechanism, lead to the reduced activity of DHRS3 by either directly competing with its substrates, altering retinoid signaling and metabolism, or affecting associated enzymatic processes, crucial for the proper function of DHRS3.
SEE ALSO...
Items 1 to 10 of 11 total
Display:
Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
---|---|---|---|---|---|---|
all-trans Retinal | 116-31-4 | sc-210778A sc-210778 | 250 mg 1 g | $126.00 $372.00 | 7 | |
Retinal acts as a competitive inhibitor for DHRS3, which is known to reduce retinal to retinol, thereby diminishing the functional activity of DHRS3 by limiting its substrate availability. | ||||||
13-cis-Retinoic acid | 4759-48-2 | sc-205568 sc-205568A | 100 mg 250 mg | $74.00 $118.00 | 8 | |
13-cis-Retinoic acid, a retinoic acid derivative, indirectly diminishes DHRS3 activity by serving as a negative regulator in the retinoid signaling pathway, where DHRS3 is a key player. | ||||||
Citral | 5392-40-5 | sc-252620 | 1 kg | $212.00 | ||
Citral, an inhibitor of retinal dehydrogenases, can indirectly inhibit DHRS3 activity by preventing the conversion of retinoids, which are substrates of DHRS3. | ||||||
Disulfiram | 97-77-8 | sc-205654 sc-205654A | 50 g 100 g | $52.00 $87.00 | 7 | |
Disulfiram inhibits aldehyde dehydrogenase, which has a downstream effect of increasing retinal levels, subsequently leading to competitive inhibition of DHRS3. | ||||||
Retinoic Acid, all trans | 302-79-4 | sc-200898 sc-200898A sc-200898B sc-200898C | 500 mg 5 g 10 g 100 g | $65.00 $319.00 $575.00 $998.00 | 28 | |
Retinoic Acid inhibits DHRS3 by elevating the levels of retinoic acid, which in turn regulates the retinoid metabolism pathway that DHRS3 is part of. | ||||||
4-Hydroxyphenylretinamide | 65646-68-6 | sc-200900 sc-200900A | 5 mg 25 mg | $104.00 $315.00 | ||
4-Hydroxyphenylretinamide decreases DHRS3 activity by modulating the retinoic acid pathway and influencing levels of retinol and its derivatives, which are substrates for DHRS3. | ||||||
Acitretin | 55079-83-9 | sc-210754 | 25 mg | $148.00 | 1 | |
Acitretin, a synthetic retinoid, diminishes DHRS3 activity by altering the retinoid metabolism in which DHRS3 functions, leading to a decrease in its enzymatic activity. | ||||||
Bexarotene | 153559-49-0 | sc-217753 sc-217753A | 10 mg 100 mg | $54.00 $245.00 | 6 | |
Bexarotene, a retinoid X receptor agonist, indirectly affects DHRS3 by modulating retinoid signaling, thus influencing the metabolic pathways that DHRS3 is involved in. | ||||||
Adapalene | 106685-40-9 | sc-203803 sc-203803A | 10 mg 50 mg | $65.00 $325.00 | 2 | |
Adapalene, through its action as a retinoid agonist, can lead to the downregulation of DHRS3 by modulating the metabolic pathways of retinoids. | ||||||
Gossypol | 303-45-7 | sc-200501 sc-200501A | 25 mg 100 mg | $114.00 $225.00 | 12 | |
Gossypol inhibits various dehydrogenase enzymes; this non-specific inhibition could extend to DHRS3, thereby diminishing its enzymatic activity. |